9M 2023 Financial Performance
9M 2023: Business update
Strong business performance in the first nine months of 2023
$
Robust revenue
performance
Double-digit growth
of strategic brands
ه
0000
Strong profit
achievements
Advancing R&D
pipeline
DKK 15bn
Revenue
DKK 10bn
68% of total revenue
+9% (+10% reported)
Revenue growth
+81% (+79% reported)
Vyepti revenue growth
+16% (+14% reported)
Strategic brands revenue growth
Positive indicators persist in
the launch of Rexulti AADAD
DKK 5bn
Adj. EBITDA
+20% (+31% reported)
Adj. EBITDA growth
32.5%
Adj. EBITDA margin
PACAP POC
data presented at the
IHC in Seoul
HLR of the two PTSD
phase III trials obtained
in September
3
Unless otherwise stated, growth rates are at CER. AADAD: agitation associated with dementia due to Alzheimer's disease. PoC: proof of concept. IHC: International Headache Congress
LundbeckView entire presentation